Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TCRT

Alaunos Therapeutics Inc

Feb 11 • 01:05PM ET

2.68

-0.04 -1.47 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NTLA EDIT BEAM PGEN KPTI FATE ADAP SGMO IMTX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.31	Insider Own	16.35%	Shs Outstand	2.21M	Perf Week	9.39%
Market Cap	5.98M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.87M	Perf Month	-5.96%
Enterprise Value	4.04M	PEG	-	EPS next Q	-	Inst Own	3.50%	Short Float	2.38%	Perf Quarter	5.93%
Income	-4.07M	P/S	598.07	EPS this Y	-	Inst Trans	-13.39%	Short Ratio	0.95	Perf Half Y	9.84%
Sales	0.01M	P/B	2.11	EPS next Y	-	ROA	-110.67%	Short Interest	0.04M	Perf YTD	-17.03%
Book/sh	1.27	P/C	3.08	EPS next 5Y	-	ROE	-145.65%	52W High	6.20 -56.77%	Perf Year	61.26%
Cash/sh	0.87	P/FCF	-	EPS past 3/5Y	62.43% 51.16%	ROIC	-145.09%	52W Low	1.31 104.00%	Perf 3Y	-97.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-70.71% -	Gross Margin	-	Volatility	8.86% 7.09%	Perf 5Y	-99.63%
Dividend TTM	-	EV/Sales	404.07	EPS Y/Y TTM	68.59%	Oper. Margin	-67883.33%	ATR (14)	0.22	Perf 10Y	-99.68%
Dividend Ex-Date	-	Quick Ratio	2.92	Sales Y/Y TTM	0.00%	Profit Margin	-67783.33%	RSI (14)	44.40	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.92	EPS Q/Q	21.82%	SMA20	-2.96%	Beta	-1.26	Target Price	1125.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-17.41%	Rel Volume	0.18	Prev Close	2.72
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	-11.74%	Avg Volume	46.89K	Price	2.68
IPO	Aug 22, 2005	Option/Short	No / Yes	EPS/Sales Surpr.	-14.29% -	Trades		Volume	5,056	Change	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Resumed	Wells Fargo	Overweight	$3

Nov-14-25 04:31PM	Ziopharm: Q3 Earnings Snapshot (Associated Press Finance) +8.42%
Aug-14-25 06:56PM	Ziopharm: Q2 Earnings Snapshot (Associated Press Finance) -6.25%
Jun-23-25 08:00AM	Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering (GlobeNewswire)
Jun-18-25 09:52AM	PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies (GlobeNewswire) +9.18%
May-14-25 08:00AM	PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (GlobeNewswire)
08:57AM	Loading…
Oct-11-24 08:57AM	Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy (TipRanks)
May-15-24 10:55PM	TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.39%
Apr-08-24 12:52PM	TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Dec-18-23 07:57AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? (InvestorPlace) +26.15%
Nov-14-23 07:56AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today? (InvestorPlace) -10.59%
07:30AM	Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives (GlobeNewswire)
Aug-14-23 04:05PM	Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives (GlobeNewswire) -64.68%
Jun-29-23 07:00AM	Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire) +14.30%
May-25-23 05:00PM	Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -16.65%
May-10-23 07:00AM	Alaunos Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
08:30AM	Loading…
May-03-23 08:30AM	Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-26-23 12:30PM	Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) +6.57%
Mar-30-23 07:00AM	Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors (GlobeNewswire)
Mar-29-23 05:30PM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April (GlobeNewswire) +6.72%
Mar-07-23 07:00AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:01PM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 (GlobeNewswire)
Feb-17-23 05:47AM	Alaunos Therapeutics, Inc.'s (NASDAQ:TCRT) largest shareholders are individual investors with 58% ownership, institutions own 22% (Simply Wall St.)
Jan-09-23 08:30AM	Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 (GlobeNewswire)
Nov-29-22 09:01AM	Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -22.78%
Nov-28-22 04:01PM	Alaunos Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.84%
Nov-14-22 07:00AM	Alaunos Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.48%
Nov-08-22 08:30AM	Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Nov-07-22 08:00AM	Alaunos Therapeutics to Present Data Highlighting its hunTR TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting (GlobeNewswire)
Sep-21-22 08:30AM	Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) -20.87%
Sep-07-22 08:30AM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +18.21%
08:00AM	Loading…
Sep-06-22 08:00AM	Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy (GlobeNewswire)
Aug-24-22 03:00PM	Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) +20.00%
Aug-15-22 07:00AM	Alaunos Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +18.18%
Aug-08-22 08:50AM	Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-04-22 05:00PM	Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations (GlobeNewswire) +8.39%
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +13.45%
Jun-30-22 07:07AM	Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt In A Risky Way? (Simply Wall St.)
Jun-27-22 08:00AM	Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 (GlobeNewswire) +17.27%
Jun-01-22 08:30AM	Alaunos Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) -8.63%
May-26-22 05:01PM	Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +11.09%
May-16-22 07:30AM	Alaunos Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -15.15%
May-12-22 11:48AM	Insiders who placed huge bets on Alaunos Therapeutics, Inc. (NASDAQ:TCRT) earlier this year would be disappointed with the 27% drop (Simply Wall St.) +5.89%
May-10-22 08:30AM	Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.16%
May-09-22 08:30AM	Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire)
May-02-22 04:31PM	Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -7.28% +12.66%
08:30AM	Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors (GlobeNewswire)
Mar-30-22 07:30AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-22-22 01:58PM	What Percentage Of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Do Insiders Own? (Simply Wall St.)
Mar-16-22 08:30AM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022 (GlobeNewswire) +8.41%
Mar-08-22 04:05PM	Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) +21.63%

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.

Open in Screener

MLAC

Mountain Lake Acquisition Corp

Feb 11 • 01:22PM ET

10.46

0.00 0.00 %

Financial • Shell Companies • USA • NASD

MLAC Mountain Lake Acquisition Corp daily Stock Chart

Held by: CUSD

Index	-	P/E	47.42	EPS (ttm)	0.22	Insider Own	24.79%	Shs Outstand	23.80M	Perf Week	0.00%
Market Cap	324.18M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	23.31M	Perf Month	0.29%
Enterprise Value	323.33M	PEG	-	EPS next Q	-	Inst Own	82.46%	Short Float	0.07%	Perf Quarter	0.53%
Income	6.84M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.20	Perf Half Y	1.75%
Sales	0.00M	P/B	1.40	EPS next Y	-	ROA	5.69%	Short Interest	0.02M	Perf YTD	0.58%
Book/sh	7.47	P/C	381.39	EPS next 5Y	-	ROE	5.91%	52W High	10.69 -2.15%	Perf Year	4.91%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	- -	ROIC	2.95%	52W Low	9.97 4.91%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.15% 0.19%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.30	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	3.14	EPS Q/Q	6980.00%	SMA20	0.11%	Beta	0.00	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	0.36%	Rel Volume	0.57	Prev Close	10.46
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	1.83%	Avg Volume	87.39K	Price	10.46
IPO	Feb 03, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	30,372	Change	0.00%

Oct-15-25 12:52PM	Digital asset treasuries are opening the gates to mainstream crypto (TheStreet)
Oct-01-25 07:00PM	Avalanche Treasury Co. Announces $675 Million+ Business Combination with Mountain Lake Acquisition Corp. with Goal to Build $1 Billion+ Ecosystem Treasury (Business Wire)

Mountain Lake Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on June 14, 2024 and is headquartered in Incline Village, NV.

TCRT

Alaunos Therapeutics Inc

MLAC

Mountain Lake Acquisition Corp

Upgrade your FINVIZ experience